evidence card · ncgs_diagnosed_by_invalid_biomarkers
Non-celiac gluten sensitivity is frequently diagnosed using biomarker tests that lack validity
H4
▲ supports
stakes moderate
2 posts scored
·
across 1 account
·
1 sources
Summary
Current expert guidance (Salerno criteria) uses double-blind placebo-controlled gluten challenge. Commercial IgG-to-gluten and similar panels are not validated for NCGS diagnosis.
Five-score assessment
Scores not yet assigned for this card. (Legacy card; will be populated on next refinement.)
Scope
Population
adults presenting with gluten-related GI symptoms
Intervention
marketed biomarker panels vs validated diagnostic approach
Outcome
diagnostic accuracy
Not supported for
- claim NCGS as a syndrome does not exist (double-blind challenge studies suggest a subset of patients is real)